
STLN Stock Forecast & Price Target
STLN Analyst Ratings
Bulls say
Starling Oncology is supported by a large, underpenetrated oncology market, with less than 1% penetration and demand tailwinds from rising cancer prevalence, utilization, and drug spend. Its 3Q26 results showed 24% revenue growth to $169.8M, adjusted EBITDA of $3.4M above expectations, and two consecutive quarters of positive EBITDA, while Specialty Pharmacy grew 44% and capitated revenue still rose 40% despite the Florida delay. The company’s differentiated care model, which has delivered 50%+ lower ED utilization and hospitalizations and $12,000+ in savings per enrolled patient, should support margin expansion as value-based contracts scale and the 2027 pipeline exceeds $1B.
Bears say
Starling Oncology is facing a negative fundamental setup because payer and physician preference could shift to other groups, limiting patient growth and expansion, while the company already lost a contract in 2024, raising the risk of further erosion. Its fairly heavy debt load constrains financial flexibility and may restrict investment in growth, even as the Dispensary business’ better margins are offset by reimbursement pressure in the pharmacy component. In addition, dependence on Medicare and Medicaid, capitation forecasting risk, and exposure to HHS, FDA, and CMS regulation create multiple operating headwinds that could pressure profitability and cash flow.
This aggregate rating is based on analysts' research of Starling Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
STLN Analyst Forecast & Price Prediction
Start investing in STLN
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Starling Oncology Inc (STLN) Forecast
STLN Analyst Forecast & Price Prediction
Start investing in STLN
Order type
Buy in
Order amount
Est. shares
0 shares